期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 117, 期 5, 页码 1440-1449出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI31245
关键词
-
资金
- NCI NIH HHS [P50 CA105009, P50 CA 105009-01] Funding Source: Medline
- NHLBI NIH HHS [P50 HL054785, K23 HL068632, R01 HL052725, R37 HL052725, P01 HL 54785, K23 HL 068632-03, R01 HL 52725] Funding Source: Medline
- NIAID NIH HHS [U19 AI067751, AI 067751] Funding Source: Medline
- NIDDK NIH HHS [R01 DK 43889, R01 DK043889] Funding Source: Medline
- PHS HHS [P01 150654] Funding Source: Medline
The Fanconi anemia (FA) pathway maintains genomic stability in replicating cells. Some sporadic breast, ovarian, pancreatic, and hematological. tumors are deficient in FA pathway function, resulting in sensitivity to DNA-damaging agents. FA pathway dysfunction in these tumors may result in hyperdependence on alternative DNA repair pathways that could be targeted as a treatment strategy. We used a high-throughput siRNA screening approach that identified ataxia telangiectasia mutated (ATM) as a critical kinase for FA pathway-deficient human fibroblasts. Human fibroblasts and murine embryonic fibroblasts deficient for the FA pathway were observed to have constitutive ATM activation and Fancg(-/-)Atm(-/-) mice were found to be nonviable. Abrogation of ATM function in FA pathway-deficient cells resulted in DNA breakage, cell cycle arrest, and apoptotic cell death. Moreover, Fanconi anemia complementation group G- (FANCG-) and FANCC-deficient pancreatic tumor lines were more sensitive to the ATM inhibitor KU-55933 than isogenic corrected lines. These data suggest that ATM and FA genes function in parallel and compensatory roles to maintain genomic integrity and cell viability. Pharmaceutical inhibition of ATM may have a role in the treatment of FA pathway-deficient human cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据